Apogee Therapeutics (NASDAQ:APGE) Price Target Raised to $130.00

Key Points

• Canaccord Genuity raised its price target on Apogee to $130 (from $89), implying roughly a 75.5% upside; other brokers have also boosted targets (Guggenheim $160, BTIG $137) and the consensus target sits at $109.31.
• Positive Phase 2 APEX 52‑week data for zumilokibart has driven analyst optimism and share momentum, but the company’s planned $300M underwritten public offering (and recent insider selling) presents dilutive near‑term risk despite the clinical win.

Apogee Therapeutics (NASDAQ:APGE - Get Free Report) had its price target lifted by investment analysts at Canaccord Genuity Group from $89.00 to $130.00 in a report issued on Tuesday,Benzinga reports. The brokerage currently has a "buy" rating on the stock. Canaccord Genuity Group's price objective points to a potential upside of 75.53% from the stock's previous close.

Several other research firms have also commented on APGE. BTIG Research reaffirmed a "buy" rating and set a $137.00 price target on shares of Apogee Therapeutics in a research report on Monday. Truist Financial assumed coverage on shares of Apogee Therapeutics in a report on Tuesday, March 17th. They set a "hold" rating and a $83.00 target price on the stock. UBS Group upgraded Apogee Therapeutics to a "strong-buy" rating in a research note on Wednesday, January 7th. Guggenheim boosted their target price on shares of Apogee Therapeutics from $130.00 to $160.00 and gave the stock a "buy" rating in a research note on Tuesday. Finally, Deutsche Bank Aktiengesellschaft started coverage on shares of Apogee Therapeutics in a research note on Tuesday, December 9th. They issued a "buy" rating and a $103.00 price target on the stock. Three research analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $109.31.

Apogee Therapeutics Price Performance

Shares of APGE stock traded down $5.18 on Tuesday, hitting $74.06. 344,728 shares of the stock traded hands, compared to its average volume of 1,014,072. The firm has a 50 day simple moving average of $71.28 and a two-hundred day simple moving average of $63.70. The firm has a market cap of $5.15 billion, a price-to-earnings ratio of -17.48 and a beta of 1.39. Apogee Therapeutics has a 52 week low of $26.20 and a 52 week high of $84.56.

Apogee Therapeutics (NASDAQ:APGE - Get Free Report) last issued its quarterly earnings results on Monday, March 2nd. The company reported ($1.03) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.05) by $0.02. Sell-side analysts forecast that Apogee Therapeutics will post -3.09 EPS for the current year.

Insider Activity at Apogee Therapeutics

In other Apogee Therapeutics news, insider Carl Dambkowski sold 5,500 shares of the firm's stock in a transaction dated Wednesday, March 4th. The shares were sold at an average price of $71.06, for a total value of $390,830.00. Following the transaction, the insider owned 209,773 shares of the company's stock, valued at $14,906,469.38. This trade represents a 2.55% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Michael Thomas Henderson sold 20,000 shares of the company's stock in a transaction dated Wednesday, March 11th. The shares were sold at an average price of $74.78, for a total transaction of $1,495,600.00. Following the completion of the sale, the chief executive officer directly owned 1,152,987 shares of the company's stock, valued at $86,220,367.86. The trade was a 1.71% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders sold 1,839,700 shares of company stock worth $140,118,083. Corporate insiders own 42.77% of the company's stock.

Institutional Trading of Apogee Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in APGE. Rockefeller Capital Management L.P. bought a new stake in Apogee Therapeutics in the fourth quarter valued at approximately $25,000. Los Angeles Capital Management LLC acquired a new position in Apogee Therapeutics during the fourth quarter worth $37,000. ANTIPODES PARTNERS Ltd lifted its stake in Apogee Therapeutics by 41.2% in the 3rd quarter. ANTIPODES PARTNERS Ltd now owns 843 shares of the company's stock valued at $33,000 after purchasing an additional 246 shares during the last quarter. Seven Fleet Capital Management LP bought a new position in shares of Apogee Therapeutics during the 4th quarter worth approximately $136,000. Finally, Ensign Peak Advisors Inc acquired a new stake in shares of Apogee Therapeutics during the 4th quarter worth about $170,000. Institutional investors and hedge funds own 79.04% of the company's stock.

More Apogee Therapeutics News

Here are the key news stories impacting Apogee Therapeutics this week:

• Positive Sentiment: Positive Phase 2 APEX Part A 52‑week data showed durable maintenance and deepening of responses with both every‑3‑month and every‑6‑month dosing (EASI‑75 maintenance 75% and 85%; vIGA 0/1 maintenance 86% and 78%), supporting zumilokibart’s competitive profile and low‑frequency dosing advantage. GlobeNewswire release Benzinga summary
• Positive Sentiment: Brokerage support: Guggenheim raised its price target to $160 with a Buy rating (large upside vs. prior levels), and BTIG reaffirmed Buy with a $137 target — analyst optimism amplifies the clinical news and can attract momentum flows. Benzinga
• Positive Sentiment: Investor research and coverage: Seeking Alpha pieces and the conference call/transcript/slideshow provide deeper reads that highlight Zumilokibart’s infrequent‑dosing commercial case and the company’s cash runway, supporting buy arguments for longer‑term upside. Seeking Alpha analysis Conference call transcript/slideshow
• Neutral Sentiment: Short interest reporting is noisy/zero in the feed and shows no clear short‑position pressure; likely not a material driver today. (Data appears inconsistent.)
• Neutral Sentiment: Valuation discussion: independent writeups examine APGE’s valuation after recent moves — useful for framing risk/reward but not new company fundamentals. Valuation article
• Negative Sentiment: Planned $300M underwritten public offering announced — while proceeds boost cash runway and fund development, the offering is dilutive and can apply downward pressure on the share price until completed. GlobeNewswire offering notice
• Negative Sentiment: Some analyst valuation work (DCF) suggests intrinsic value nearer to ~$73/share, implying limited near‑term upside absent M&A or further positive catalysts — a caution for investors who view the post‑data market cap as elevated. Seeking Alpha valuation note

Apogee Therapeutics Company Profile

Apogee Therapeutics, Inc is a clinical-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics that selectively target the nuclear receptor RORγt, a master regulator of T cell-driven inflammatory pathways. By modulating RORγt activity, Apogee aims to offer an oral treatment option for patients with autoimmune and inflammatory skin disorders.

The company's lead candidate, APG-157, is an oral RORγt inverse agonist currently undergoing early-stage clinical evaluation for moderate to severe plaque psoriasis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.